Home
Drugs
Secukinumab

Secukinumab

Drug

Related News

Bimekizumab Durable Improvements in Psoriasis Over 3 Years in BE RADIANT Trial

Jul 14, 2026

In the BE RADIANT phase 3b trial, bimekizumab provided greater and durable improvements in patient-reported symptoms, skin clearance, and quality of life over 3 years compared with secukinumab in moderate to severe plaque psoriasis. At week 4, significantly more patients on bimekizumab achieved complete absence of itching, skin pain, and scaling. The benefits were sustained through 3 years, including after patients switched from secukinumab.

Phase IIb Trial Shows Low-Dose IL-2 Effective in SLE

Jun 23, 2026

A phase IIb trial demonstrated that low-dose IL-2 therapy produced dose-dependent improvements in SLE patients, with 69.7% achieving SRI-4 response at the highest dose versus 23.5% on placebo. A separate systematic review found IL-17 inhibitors remain potential SLE treatment options, though efficacy data are limited.

Biosimilar and biologic updates include approvals, review decisions and licensing deals

Apr 29, 2026

Recent biosimilar and biologic developments included Health Canada approval of denosumab biosimilars, FDA review actions, and new licensing and commercialisation agreements. Other updates covered court, trial and reimbursement agenda decisions.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT07489573	Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa	RECRUITING	PHASE4
NCT07352566	Utilization of a Microdevice for Psoriasis and Atopic Dermatitis	NOT_YET_RECRUITING	PHASE4
NCT07138898	Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty	RECRUITING	PHASE2
NCT06905288	Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.	RECRUITING
NCT06751238	Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).	RECRUITING	PHASE1
NCT06331312	Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)	ACTIVE_NOT_RECRUITING	PHASE3
NCT05622708	A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission	ACTIVE_NOT_RECRUITING	PHASE4
NCT04179175	Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa	COMPLETED	PHASE3